Performance Enhancing Drugs Market Research Report Information By Types (Ergogenic Aids, Nootropic), By Products (Pills, Injections, Patches), By End Users (Athletes, Body Builders, Students, Militaries), and Others- Forecast Till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Performance Enhancing Drugs Market, by Type

6.1 Introduction

6.2 Ergogenic Aids

Market Estimates & Forecast, 2020 – 2027

6.2.1 Anabolic Steroids

6.2.2 Dehydroepiandrosterone (DHEA)

6.2.3 Human Growth Hormone

6.2.4 Others

6.3 Nootropic

Market Estimates & Forecast, 2020 – 2027

6.3.1 Racetams

6.3.2 Ampakines

6.3.3 Choline & Acetylcholine Intermediates

6.3.4 Others

6.4 Others

Chapter 7. Global Performance Enhancing Drugs Market, by Products

7.1 Introduction

7.2 Pills

Market Estimates & Forecast, 2020 – 2027

7.3 Injections

Market Estimates & Forecast, 2020 – 2027

7.4 Patches

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Market Estimates & Forecast, 2020 – 2027

Chapter 8 Global Performance Enhancing Drugs Market, by End User

8.1 Introduction

8.2 Athletes

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Body Builders

8.2.2 Market Estimates & Forecast, 2020 – 2027

8.4 Students

8.2.3 Market Estimates & Forecast, 2020 – 2027

8.5 Militaries

8.2.4 Market Estimates & Forecast, 2020 – 2027

8.6 Others

8.2.5 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Performance Enhancing Drugs Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Taj Pharmaceuticals Limited.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Balkan Pharmaceuticals.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bayer AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 AstraZeneca

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Novo Nordisk A/S

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 BrainAlert, LLC

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Douglas Laboratories.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Onnit Labs, LLC.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8 Eli Lilly and Company.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Performance Enhancing Drugs Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 Performance Enhancing Drugs Industry Synopsis, 2020 – 2027

Table 2 Global Performance Enhancing Drugs Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Performance Enhancing Drugs Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 6 Global Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 8 North America Performance Enhancing Drugs by Products, 2020 – 2027, (USD Million)

Table 9 North America Performance Enhancing Drugs by End Users, 2020 – 2027, (USD Million)

Table 10 US Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 11 US Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 12 US Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 14 Canada Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 15 Canada Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 17 South America Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 18 South America Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table19 Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 20 Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 21 Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 23 Western Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 24 Western Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Performance Enhancing Drugs Market

Figure 3 Segmentation Market Dynamics for Global Performance Enhancing Drugs Market

Figure 4 Global Performance Enhancing Drugs Market Share, by Type 2020

Figure 5 Global Performance Enhancing Drugs Market Share, by Products 2020

Figure 6 Global Performance Enhancing Drugs Market Share, by End Users, 2020

Figure 7 Global Performance Enhancing Drugs Market Share, by Region, 2020

Figure 8 North America Performance Enhancing Drugs Market Share, by Country, 2020

Figure 9 Europe Performance Enhancing Drugs Market Share, by Country, 2020

Figure 10 Asia Pacific Performance Enhancing Drugs Market Share, by Country, 2020

Figure 11 Middle East & Africa Rickets Market Share, by Country, 2020

Figure 12 Global Performance Enhancing Drugs Market: Company Share Analysis, 2020 (%)

Figure 13 Taj Pharmaceuticals Limited. : Key Financials

Figure 14 Taj Pharmaceuticals Limited. : Segmental Revenue

Figure 15 Taj Pharmaceuticals Limited. : Geographical Revenue

Figure 16 Balkan Pharmaceuticals. : Key Financials

Figure 17 Balkan Pharmaceuticals. : Segmental Revenue

Figure 18 Balkan Pharmaceuticals. : Geographical Revenue

Figure 19 Bayer AG. : Key Financials

Figure 20 Bayer AG. : Segmental Revenue

Figure 21 Bayer AG. : Geographical Revenue

Figure 22 AstraZeneca: Key Financials

Figure 23 AstraZeneca: Segmental Revenue

Figure 24 AstraZeneca: Geographical Revenue

Figure 25 Novo Nordisk A/S: Key Financials

Figure 26 Novo Nordisk A/S: Segmental Revenue

Figure 27 Novo Nordisk A/S: Geographical Revenue

Figure 28 BrainAlert, LLC: Key Financials

Figure 29 BrainAlert, LLC: Segmental Revenue

Figure 30 BrainAlert, LLC: Geographical Revenue

Figure 31 Douglas Laboratories.: Key Financials

Figure 32 Douglas Laboratories.: Segmental Revenue

Figure 33 Douglas Laboratories.: Geographical Revenue

Figure 34 Onnit Labs, LLC. : Key Financials

Figure 35 Onnit Labs, LLC.: Segmental Revenue

Figure 36 Onnit Labs, LLC. : Geographical Revenue

Figure 37 Eli Lilly and Company. : Key Financials

Figure 38 Eli Lilly and Company. : Segmental Revenue

Figure 39 Eli Lilly and Company. : Geographical Revenue